The musician-turned-biotech-founder waiting to fundraise

About this episode

Aloe Blacc discusses his transition from musician to biotech founder and the challenges of fundraising in the biotech industry.

When Grammy-nominated singer-songwriter Aloe Blacc got COVID despite being vaccinated and boosted, he tried to fund research for a better solution. What he quickly found out? You can't just write a check in biotech. Regulators require a commercialization plan, and philanthropy doesn't move science through clinical trials or get you a license on university IP. Now, he's bootstrapping a cancer drug platform targeting pancreatic cancer, a disease that kills 90% of its patients, and intentionally waiting to raise from his network until peer-reviewed papers can make his case. On this episode of TechCrunch's Equity podcast, Rebecca Bellan sits down with Aloe Blacc to talk about what happens when a creator decides to build instead of just invest, how Aloe is watching AI reshape both the biotech and music industries in real time, and his thoughts on who actually wins. Listen to the full episode to hear: How he’s navigating a world where credibility is earned in data, not fame How a University of Houston molecule discovery platform could cut years off drug development timelines Why he thinks record labels, not artists or AI companies, will ultimately control the economics of AI-generated…

People in this episode

Host: Rebecca Bellan

Guest: Aloe Blacc

Topics covered

• biotech
• music industry
• AI
• cancer drug development
• entrepreneurship

Keywords

• COVID
• commercialization plan
• clinical trials
• pancreatic cancer
• data credibility
• AI-generated music

Mentioned in this episode

Products: cancer drug platform, University of Houston molecule discovery platform

Books & works: Grammy

More episodes of Equity

• The SpaceX IPO has finally arrived · June 12, 2026 · 20 min
• It’s hot IPO summer, and the MANGOS are ripe · June 12, 2026 · 34 min
• Andrew Yang on Noble Mobile, UBI, and why he's done waiting for policy to catch up · June 10, 2026 · 29 min
• The 'together tech' wave might be the most intriguing startup bet of 2026 · June 5, 2026 · 34 min
• Every defense startup wants to be the next Anduril. Here's what one of its earliest backers is looking for now. · June 3, 2026 · 39 min
• Does your CEO have AI psychosis? Aaron Levie thinks most of them do. · May 29, 2026 · 38 min